The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
That worked. Like we went very quickly from BRAF inhibitor monotherapy to BRAF-MEK combination therapy, including overall survival improvements that were as big as the overall survival improvement BRAF inhibitor monotherapy. Any case, BRAF-MEK combination in the adjuvant setting prevents relapse by 50%, and patients receive a year of therapy, stop treatment, And there's a persistent gap there in terms of cured patients.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.